Prior lines of treatment, concomitant therapy administered with HAR immunotherapy, and best response by patient
| Patient no. . | Best response . | Prior lines of treatment . | Dose of HAR, cells in millions . | Concomitant treatment . |
|---|---|---|---|---|
| 1 | SD | 4 | 150 | None |
| 2 | PD | 2 | 150 | None |
| 3 | SD | 1 | 150 | None |
| 4 | SD | 1 | 150 | Nivolumab |
| 5 | SD | 1 | 300 | Nivolumab |
| 6 | PD | 2 | 300 | Nivolumab |
| 7 | SD | 0a | 300 | Nivolumab |
| 8 | PD | 2 | 300 | Nivolumab |
| 9 | PD | 1 | 300 | Nivolumab |
| 10 | SD | 1 | 300 | None |
| 11 | SD | 1 | 300 | Nivolumab |
| 12 | PD | 4 | 300 | Nivolumab |
| 13 | PD | 4 | 300 | Nivolumab; cabozantinib |
| 14 | PD | 1 | 300 | Sunitinib |
| 15 | SD | 1 | 300 | None |
| 16 | PD | 3 | 300 | Nivolumab |
| 17 | PD | 1 | 300 | Nivolumab |
| 18 | PR | 0a | 300 | Nivolumab |
| Patient no. . | Best response . | Prior lines of treatment . | Dose of HAR, cells in millions . | Concomitant treatment . |
|---|---|---|---|---|
| 1 | SD | 4 | 150 | None |
| 2 | PD | 2 | 150 | None |
| 3 | SD | 1 | 150 | None |
| 4 | SD | 1 | 150 | Nivolumab |
| 5 | SD | 1 | 300 | Nivolumab |
| 6 | PD | 2 | 300 | Nivolumab |
| 7 | SD | 0a | 300 | Nivolumab |
| 8 | PD | 2 | 300 | Nivolumab |
| 9 | PD | 1 | 300 | Nivolumab |
| 10 | SD | 1 | 300 | None |
| 11 | SD | 1 | 300 | Nivolumab |
| 12 | PD | 4 | 300 | Nivolumab |
| 13 | PD | 4 | 300 | Nivolumab; cabozantinib |
| 14 | PD | 1 | 300 | Sunitinib |
| 15 | SD | 1 | 300 | None |
| 16 | PD | 3 | 300 | Nivolumab |
| 17 | PD | 1 | 300 | Nivolumab |
| 18 | PR | 0a | 300 | Nivolumab |
aPatient had nephrectomy prior to the study.
Abbreviations: HAR, HyperAcute Renal; PD, progressive disease; PR, partial response; SD, stable disease.
Prior lines of treatment, concomitant therapy administered with HAR immunotherapy, and best response by patient
| Patient no. . | Best response . | Prior lines of treatment . | Dose of HAR, cells in millions . | Concomitant treatment . |
|---|---|---|---|---|
| 1 | SD | 4 | 150 | None |
| 2 | PD | 2 | 150 | None |
| 3 | SD | 1 | 150 | None |
| 4 | SD | 1 | 150 | Nivolumab |
| 5 | SD | 1 | 300 | Nivolumab |
| 6 | PD | 2 | 300 | Nivolumab |
| 7 | SD | 0a | 300 | Nivolumab |
| 8 | PD | 2 | 300 | Nivolumab |
| 9 | PD | 1 | 300 | Nivolumab |
| 10 | SD | 1 | 300 | None |
| 11 | SD | 1 | 300 | Nivolumab |
| 12 | PD | 4 | 300 | Nivolumab |
| 13 | PD | 4 | 300 | Nivolumab; cabozantinib |
| 14 | PD | 1 | 300 | Sunitinib |
| 15 | SD | 1 | 300 | None |
| 16 | PD | 3 | 300 | Nivolumab |
| 17 | PD | 1 | 300 | Nivolumab |
| 18 | PR | 0a | 300 | Nivolumab |
| Patient no. . | Best response . | Prior lines of treatment . | Dose of HAR, cells in millions . | Concomitant treatment . |
|---|---|---|---|---|
| 1 | SD | 4 | 150 | None |
| 2 | PD | 2 | 150 | None |
| 3 | SD | 1 | 150 | None |
| 4 | SD | 1 | 150 | Nivolumab |
| 5 | SD | 1 | 300 | Nivolumab |
| 6 | PD | 2 | 300 | Nivolumab |
| 7 | SD | 0a | 300 | Nivolumab |
| 8 | PD | 2 | 300 | Nivolumab |
| 9 | PD | 1 | 300 | Nivolumab |
| 10 | SD | 1 | 300 | None |
| 11 | SD | 1 | 300 | Nivolumab |
| 12 | PD | 4 | 300 | Nivolumab |
| 13 | PD | 4 | 300 | Nivolumab; cabozantinib |
| 14 | PD | 1 | 300 | Sunitinib |
| 15 | SD | 1 | 300 | None |
| 16 | PD | 3 | 300 | Nivolumab |
| 17 | PD | 1 | 300 | Nivolumab |
| 18 | PR | 0a | 300 | Nivolumab |
aPatient had nephrectomy prior to the study.
Abbreviations: HAR, HyperAcute Renal; PD, progressive disease; PR, partial response; SD, stable disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
